Skip to main content

Treatment of Infectious Complications of the Hematopoietic Syndrome

  • Chapter
Treatment of Radiation Injuries
  • 76 Accesses

Abstract

From a strictly therapeutic point of view, bone marrow failure resulting from irradiation presents three main challenges to the clinician: (1) to correct any metabolic disturbances, either of the hydroelectrolytic compartment or of a nutritional nature; (2) to compensate for cytopenias, particularly of granulocytes and platelets; and (3) to prevent or treat infections. These goals can be achieved only through supportive, substitutive, or compensative therapies. In this chapter, I summarize the principal therapies that have been adopted for preventing and treating the infectious complications of the hematopoietic syndrome—complications that derive basically from transient granulocytopenia, which usually lasts for about 2 weeks. Severe bone marrow failure appears when significant body volumes receive doses of about 4-6 Gy within a short period of time. The clinician must bear in mind that the hematopoietic syndrome can put the life of an irradiated person at risk. Patients with severe granulocytopenia (less than 100/pL) tend to develop early and possibly fatal infectious fevers. Despite the possibility that a concomitant hemorrhage might occur, which certainly would contribute to an increase in the mortality rate, it has seldom been observed in accidentally irradiated persons. Infectious complications are responsible for most fatalities. The basic rules adopted for preventing and treating infectious complications observed in accidentally irradiated persons do not differ substantially from those used for treating cancer patients who present granulocytopenia as a consequence of either the underlying disease or their chemotherapy or radiotherapy regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schimpff, S. C., Satterlee, W., Young, V. M., et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Eng J Med 284: 1061–1065, 1971.

    Article  CAS  Google Scholar 

  2. Hubner, K. F., and Fry, S. A., Eds. The Medical Basis for Radiation Accident Preparedness. Elsevier North Holland, Inc., New York, 1980.

    Google Scholar 

  3. Rubin, M., Hathorn, J. W., and Pizzo, P. A. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6 (2): 167–184, 1988.

    CAS  Google Scholar 

  4. Pizzo, P. A., Hathorn, J. W., Hiemenz, J., et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Eng J Med 315 (9): 552–558, 1986.

    Article  CAS  Google Scholar 

  5. Dejace, P., and Klastersky, J. Comparative review of combination therapy: Two beta-lactams versus beta-lactam plus aminoglycoside. Am J Med 80 (6B): 29–38, 1986.

    Article  PubMed  CAS  Google Scholar 

  6. Wade, J. C., Standiford, H. C., Drusano, G. L., et al. Potential of imipenem as a single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med 78 (5A): 62–72, 1985.

    Article  PubMed  CAS  Google Scholar 

  7. Karp, J. E., Merz, W. G., Hendricksen, C., et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 106: 1–7, 1987.

    Article  PubMed  CAS  Google Scholar 

  8. Rubin, M., Hathorn, J. W., Marshall, D., et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108: 30–35, 1988.

    Article  PubMed  CAS  Google Scholar 

  9. Wong, K. K., and Hirsch, M. S. Herpes virus infections in patients with neoplastic diseases. Diagnosis and therapy. Am J Med 76: 464–478, 1984.

    Article  PubMed  CAS  Google Scholar 

  10. Winston, D. J., Ho, W. G., and Gale, R. P. Therapeutic granulocyte transfusions for documented infections. Ann Intern Med 97: 509–515, 1982.

    Article  PubMed  CAS  Google Scholar 

  11. Butturini, A., DeSouza, P. C., Gale, R. P., et al. Use of recombinant granulocyte-macrophage colony-stimulating factor in the Brazil radiation accident. Lancet 11: 471–475, 1988.

    Article  Google Scholar 

  12. Grabstein, K. H., Urdal, D. L., Tushiaski, R. J., et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506–508, 1986.

    Article  PubMed  CAS  Google Scholar 

  13. Weisbart, R. H., Golde, D. W., Clark, S. C., et al. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 314: 361–363, 1985.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media New York

About this chapter

Cite this chapter

Oliveira, A.B. (1990). Treatment of Infectious Complications of the Hematopoietic Syndrome. In: Browne, D., Weiss, J.F., MacVittie, T.J., Pillai, M.V. (eds) Treatment of Radiation Injuries. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0864-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-0864-3_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-0866-7

  • Online ISBN: 978-1-4899-0864-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics